Caretek Medical Ltd, an Oxford-based company developing an innovative needle-free drug delivery system known as ImplaJect®, today announced the selection of Sumatriptan Succinate as its lead drug compound at the Needle-Free and Auto Injector Conference in London. Sumatriptan is currently prescribed in tablet form to treat migraine, a common condition that affects around 12% of the UK population, and Caretek now plans to develop a solid form of the drug that will be suitable for patients to inject using the company’s patented ImplaJect® device. The development should enable many thousands of migraine sufferers to enjoy fast, effective relief from their symptoms.
